Growth hormone therapy and chromosomal mosaicism in turner syndrome: 25 years of growth outcomes in Taiwan
Growth hormone treatment in TS is beneficial, but final adult height is complex. Karyotype, including mosaicism, isn't a primary driver of adult height; instead, factors such as bone age at treatment initiation, pre-treatment height, and mid-parental height are stronger predictors. This emphasizes the need for early diagnosis, individualized treatment plans focusing on clinical assessments, and appropriately timed hormonal interventions.
Authors
- Ying-Hua Huang (ORCID: https://orcid.org/0000-0003-0430-9745)
- Fu‐Sung Lo (ORCID: https://orcid.org/0000-0002-5548-9611)
- Yu‐Ting Chang (ORCID: https://orcid.org/0000-0002-5912-3406)
Institutions
- Chang Gung University (TW)
- Taipei Medical University Hospital (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fendo.2025.1640414
- Primary Topic
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Type
- article
- Field-Weighted Citation Impact
- 0.00